07:00 , Sep 14, 2009 |  BioCentury  |  Finance

Ebb & Flow

Besides rejecting a $14.50 per share takeover bid from Biogen Idec Inc. (NASDAQ:BIIB) last week, Facet Biotech Corp. (NASDAQ:FACT) made a couple of other moves to strengthen its position. The board put a poison pill...
07:00 , Aug 3, 2009 |  BioCentury  |  Finance

Ebb & Flow

Cumberland Pharmaceuticals Inc. is hoping to capitalize on both the market upswing and the June FDA approval of its Caldolor IV ibuprofen to get an IPO out the door. The last substantial IPO was almost a...
07:00 , May 7, 2007 |  BioCentury  |  Finance

Ebb & Flow

Five executives at MedImmune (MEDI) will be receiving more than $280 million when the $15.6 billion acquisition by AstraZeneca (LSE:AZN; AZN) closes. By comparison, the biotech sector raised a total of $566 million last week,...
07:00 , Sep 8, 1998 |  BC Week In Review  |  Company News

Therapeutic Antibodies board of directors update

Therapeutic Antibodies Inc. (LSE:TAB), Nashville, Tenn.   Business: Infectious diseases   Resigned: Martin Brown as chairman, while remaining a director   Appointed: Stuart Wallis as chairman, former CEO of Fisons plc   Resigned: Thomas Andrews, Harry Browne, Robert Hilton,...